Immune Protein IL-17A Responsible for Lethal Side Effects of Gastric Cancer
Researchers in Japan discovered that the pro-inflammatory cytokine IL-17A plays a role in promoting peritoneal spread in gastric cancer, and they suggested... Read More
Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.
Effect of Lifestyle Factors and Garlic Supplementation on Gastric Cancer Incidence
A study of more than 3,000 people found that those who took garlic supplements regularly were protected from gastric cancer, provided they... Read More
Epstein-Barr virus rewires host epigenomes to drive stomach cancer
Epstein-Barr virus is known to raise the risk of gastric cancer. A recent study explains how the virus “rewires” the epigenome to... Read More
Fluctuating expression of miR-584 in primary and high-grade gastric cancer
A recent study found that H. Pylori infection raises levels of a particular miRNA, which could be used as a biomarker for... Read More
Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
Harvard researchers found that people with a history of dental problems also face an increased risk of esophageal and gastric cancer.
Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric Cancer
Gastric cancer patients taking the immune-boosting drug Opdivo in a clinical trial had a disease control rate of 39%, according to a... Read More
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
Drug-Drug Interactions to Avoid in Patients With GI Cancer
People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Adding Herceptin to chemotherapy in gastric cancer patients with ERBB2-positive tumors produced an 85% response rate.